Eicosapentaenoic acid-enriched high-density lipoproteins exhibit anti-atherogenic properties

Circulation Journal

Volumn 82, Issue 2, 2018, Pages 596-601

  Tanaka, Nobuaki ^a   Irino, Yasuhiro ^a   Shinohara, Masakazu ^a   Tsuda, Shigeyasu ^a   Mori, Takeshige ^a   Nagao, Manabu ^a   Oshita, Toshihiko ^a   Mori, Kenta ^a   Hara, Tetsuya ^a   Toh, Ryuji ^a   Ishida, Tatsuro ^a   Hirata, Ken Ichi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

High density lipoprotein (HDL); Inflammation; Lipids; Lipoproteins; Omega 3 fatty acid

Indexed keywords

APOLIPOPROTEIN A1; ARACHIDONIC ACID; CHOLESTEROL; CHOLIC ACID; HIGH DENSITY LIPOPROTEIN; ICOSAPENTAENOIC ACID; LINOLEIC ACID; OLEIC ACID; PALMITIC ACID; PHOSPHATIDYLCHOLINE; STEARIC ACID; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; 17,18-DIHYDROXYEICOSAPENTAENOIC ACID; UNSATURATED FATTY ACID;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; FATTY ACID ANALYSIS; HEART PROTECTION; INFLAMMATION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MASS FRAGMENTOGRAPHY; MULTIPLE REACTION MONITORING; PARTICLE SIZE; REAL TIME POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ATHEROSCLEROSIS; BIOSYNTHESIS; CELL CULTURE; HUMAN; METABOLISM;

ATHEROSCLEROSIS; CELLS, CULTURED; CHOLESTEROL; EICOSAPENTAENOIC ACID; FATTY ACIDS, UNSATURATED; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; VASCULAR CELL ADHESION MOLECULE-1;

EID: 85041039358     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-17-0294     Document Type: Article

References (29)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study. Am J Med 1977; 62: 707 – 714.
2. Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. HDL-cholesterol as a marker of coronary heart disease risk: The Quebec cardiovascular study. Atherosclerosis 2000; 153: 263 – 272.
3. Gotto AM Jr. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: A working group report. Circulation 2001; 103: 2213 – 2218.
4. Annema W, von Eckardstein A. High-density lipoproteins: Multifunctional but vulnerable protections from atherosclerosis. Circ J 2013; 77: 2432 – 2448.
5. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364: 127 – 135.
6. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014; 371: 2383 – 2393.
7. Salahuddin T, Natarajan B, Playford MP, Joshi AA, Teague H, Masmoudi Y, et al. Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis. Eur Heart J 2015; 36: 2662 – 2665.
8. Bhatt A, Rohatgi A. HDL cholesterol efflux capacity: Cardiovascular risk factor and potential therapeutic target. Curr Atheroscler Rep 2016; 18: 2.
9. Zuliani G, Galvani M, Leitersdorf E, Volpato S, Cavalieri M, Fellin R. The role of polyunsaturated fatty acids (PUFA) in the treatment of dyslipidemias. Curr Pharm Des 2009; 15: 4087 – 4093.
10. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Subanalysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008; 200: 135 – 140.
11. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007; 369: 1090 – 1098.
12. Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012; 110: 984 – 992.
13. Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: Effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs 2013; 13: 37 – 46.
14. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011; 108: 682 – 690.
15. Tanaka N, Ishida T, Nagao M, Mori T, Monguchi T, Sasaki M, et al. Administration of high dose eicosapentaenoic acid enhances anti-inflammatory properties of high-density lipoprotein in Japanese patients with dyslipidemia. Atherosclerosis 2014; 237: 577 – 583.
16. Swanson D, Block R, Mousa SA. Omega-3 fatty acids EPA and DHA: Health benefits throughout life. Adv Nutr 2012; 3: 1 – 7.
17. Cavigiolio G, Shao B, Geier EG, Ren G, Heinecke JW, Oda MN. The interplay between size, morphology, stability, and functionality of high-density lipoprotein subclasses. Biochemistry 2008; 47: 4770 – 4779.
18. Mori K, Ishida T, Yasuda T, Hasokawa M, Monguchi T, Sasaki M, et al. Serum trans-fatty acid concentration is elevated in young patients with coronary artery disease in Japan. Circ J 2015; 79: 2017 – 2025.
19. Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am J Physiol Cell Physiol 2014; 307: C39 – C54.
20. Shinohara M, Serhan CN. Novel endogenous proresolving molecules: Essential fatty acid-derived and gaseous mediators in the resolution of inflammation. J Atheroscler Thromb 2016; 23: 655 – 664.
21. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 2005; 201: 713 – 722.
22. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature 2014; 510: 92 – 101.
23. Miyazaki M, Nakano M, Fukuda M, Handa T. Smaller discoidal high-density lipoprotein particles form saddle surfaces, but not planar bilayers. Biochemistry 2009; 48: 7756 – 7763.
24. Baker PW, Rye KA, Gamble JR, Vadas MA, Barter PJ. Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. J Lipid Res 2000; 41: 1261 – 1267.
25. Isobe Y, Arita M, Matsueda S, Iwamoto R, Fujihara T, Nakanishi H, et al. Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxye-icosapentaenoic acid. J Biol Chem 2012; 287: 10525 – 10534.
26. Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine 2015; 10: 975 – 999.
27. Favari E, Calabresi L, Adorni MP, Jessup W, Simonelli S, Franceschini G, et al. Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry 2009; 48: 11067 – 11074.
28. Du XM, Kim MJ, Hou L, Le Goff W, Chapman MJ, Van Eck M, et al. HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. Circ Res 2015; 116: 1133 – 1142.
29. Marmillot P, Patel S, Lakshman MR. Reverse cholesterol transport is regulated by varying fatty acyl chain saturation and sphingomyelin content in reconstituted high-density lipoproteins. Metabolism 2007; 56: 251 – 259.